- Home
- BOLD vs AREN Comparison
BOLD vs AREN Comparison
Compare BOLD & AREN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BOLD | AREN |
|---|---|---|
| Founded | 2018 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.8M | 53.3M |
| IPO Year | 2024 | 2017 |
Fundamental Metrics
Financial Performance| Metric | BOLD | AREN |
|---|---|---|
| Price | $2.74 | $1.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $4.00 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 252.7K | 121.7K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 32.47 | ★ 191.93 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $16,892,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $5.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 27.46 |
| 52 Week Low | $0.96 | $0.81 |
| 52 Week High | $2.97 | $7.61 |
Technical Indicators
Market Signals| Indicator | BOLD | AREN |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.
About AREN The Arena Group Holdings Inc.
The Arena Group Holdings Inc is a tech-powered media company that fuses technology, iconic brands, and marketing to deliver vibrant content and experiences that reach million users each month. The company creates robust digital destinations that delight consumers with powerful journalism, news about things such as favorite sports teams, advice on investing, the inside scoop on personal finance, and the latest on lifestyle essentials. The company has four reportable segments: Sports & Leisure, Finance, Lifestyle, and Platform & Other. The company generates revenue from Sports & Leisure. Geographically, the company operates in United States; and Others. It generates maximum revenue from United States.